Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Negative Symptoms

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,958 result(s) found for: Negative Symptoms. Displaying page 77 of 148.
    «« First « Previous 73  74  75  76  77  78  79  80  81  Next» Last»»
    EudraCT Number: 2016-004161-68 Sponsor Protocol Number: AG013-ODOM-201 Start Date*: 2018-10-31
    Sponsor Name:Oragenics, Inc.
    Full Title: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cance...
    Medical condition: Oral mucositis (OM) induced by chemoradiation therapy (CRT) used for the treatment of head and neck cancers (HNC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-004439-22 Sponsor Protocol Number: CAIN457F2312 Start Date*: 2013-04-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III randomized, double-blind, placebo-controlled multicenter study of subcutaneous secukinumab in prefilled syringes to demonstrate the efficacy at 24 weeks and to assess the long term effi...
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) CZ (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-002911-33 Sponsor Protocol Number: ABT-gpASIT011 Start Date*: 2018-12-18
    Sponsor Name:ASIT biotech S.A.
    Full Title: A multicentre, international, randomised, double-blind, placebo controlled study to demonstrate the clinical efficacy and safety of subcutaneous immunotherapy with gpASIT+™ in patients with grass p...
    Medical condition: Treatment of seasonal grass pollen-induced rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10019170 Hay fever LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000149-12 Sponsor Protocol Number: CXA30007 Start Date*: 2005-04-24
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase III, 12-week, Multicentre, Double-blind, Double-dummy, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group study to investigate the Efficacy and Safety of GW406381 1mg, 5m...
    Medical condition: Osteoarthritis of the Knee
    Disease: Version SOC Term Classification Code Term Level
    7.1 10023476 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) DK (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003298-22 Sponsor Protocol Number: GLPG3970-CL-207 Start Date*: 2021-01-15
    Sponsor Name:Galapagos NV
    Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks ...
    Medical condition: Primary Sjogren's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) HU (Completed) GR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003742-17 Sponsor Protocol Number: TV50717-CNS-30080 Start Date*: 2019-07-12
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
    Medical condition: Dyskinesia in cerebral palsy (DCP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10068804 Athetoid cerebral palsy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) PL (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002639-48 Sponsor Protocol Number: 54767414AMY2009 Start Date*: 2022-07-25
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis
    Medical condition: Amyloid Light Chain Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004870 10083938 Amyloid light-chain amyloidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-001441-12 Sponsor Protocol Number: OP0595-5 Start Date*: 2023-03-10
    Sponsor Name:Meiji Seika Pharma Co., Ltd.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Compli...
    Medical condition: Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10021881 - Infections and infestations 10080628 Complicated urinary tract infection LLT
    20.1 10021881 - Infections and infestations 10001032 Acute pyelonephritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) BG (Trial now transitioned) SK (Trial now transitioned) CZ (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004542-15 Sponsor Protocol Number: SGN22E-003 Start Date*: 2020-08-03
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally a...
    Medical condition: Urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046723 Urothelial carcinoma ureter LLT
    20.0 100000004864 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003097-41 Sponsor Protocol Number: EFC14335 Start Date*: 2017-02-20
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination with Pomalidomide and Low-dose Dexamethasone versus Pomalidomide and Low-dose Dexamethasone in Pa...
    Medical condition: Haematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) PT (Completed) ES (Completed) CZ (Completed) NO (Completed) GB (GB - no longer in EU/EEA) SK (Completed) BE (Completed) DK (Completed) FR (Ongoing) GR (Completed) DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005007-41 Sponsor Protocol Number: DB2116960 Start Date*: 2013-06-26
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomised, Double Blind, Double Dummy, Parallel Group Study Comparing UMEC/VI (A Fixed Combination Of Umeclidinium and Vilanterol) With Tiotropium In COPD Subjects Who Continue To Have Sympto...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD) which may also be called emphysema or chronic bronchitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Prematurely Ended) EE (Completed) NL (Completed) ES (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001832-27 Sponsor Protocol Number: AT-202 Start Date*: 2023-01-20
    Sponsor Name:Allecra Therapeutics SAS
    Full Title: A Single Group Treatment, Phase 2 study to investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam administered by intra-venous infusion over 2 hours in Male or Female Part...
    Medical condition: Complicated urinary tract infections including acute pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10037597 Pyelonephritis acute PT
    20.0 10021881 - Infections and infestations 10046577 Urinary tract infections HLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000590-39 Sponsor Protocol Number: CLL2-BIO Start Date*: 2016-01-25
    Sponsor Name:University of Cologne
    Full Title: A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofat...
    Medical condition: Fit and unfit patients with previously untreated or relapsed/refractory CLL requiring treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003133-28 Sponsor Protocol Number: CLL2-BAAG Start Date*: 2018-12-17
    Sponsor Name:Universität zu Köln
    Full Title: A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab), acalabrutinib (ACP-196) and ABT-1...
    Medical condition: Patients with relapsed/refractory CLL requiring treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000580-40 Sponsor Protocol Number: CLL2-BAG Start Date*: 2015-04-23
    Sponsor Name:University of Cologne
    Full Title: A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed ...
    Medical condition: Fit and unfit patients with previously untreated or relapsed/refractory CLL requiring treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004555-35 Sponsor Protocol Number: A8501001 Start Date*: 2005-12-15
    Sponsor Name:Pfizer Inc
    Full Title: International, randomized, open-label, Phase 3 trial of paclitaxel/carboplatin plus PF-3512676 versus paclitaxel/carboplatin alone as first-line treatment of patients with advanced non-small cell l...
    Medical condition: First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004557-10 Sponsor Protocol Number: A8501002 Start Date*: 2006-02-21
    Sponsor Name:Pfizer Inc
    Full Title: International, randomized, open-label, Phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lun...
    Medical condition: First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SK (Completed) ES (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) AT (Completed) PT (Prematurely Ended) BE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000284-32 Sponsor Protocol Number: SHP634-401 Start Date*: 2018-02-05
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinan...
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051315 Congenital hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10075900 Primary hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) SE (Completed) DK (Completed) ES (Completed) NO (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003708-29 Sponsor Protocol Number: B7981005 Start Date*: 2017-04-18
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study of Oral PF-06651600 and PF-06700841 as Induction and Chronic Therapy in Subjects with Moderate to Severe...
    Medical condition: Moderate to severe Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) DK (Completed) DE (Completed) AT (Completed) PL (Completed) HU (Completed) ES (Completed) NL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001694-24 Sponsor Protocol Number: D1050302 Start Date*: 2014-03-11
    Sponsor Name:SUNOVION PHARMACEUTICALS INC.
    Full Title: A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF LURASIDONE IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRIT...
    Medical condition: SCHIZOPHRENIA AND IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) IT (Prematurely Ended) BG (Completed) Outside EU/EEA HU (Completed) GB (Completed) DE (Completed) PL (Completed) BE (Completed) FR (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 73  74  75  76  77  78  79  80  81  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 10:02:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA